

Wetenschappelijk overzicht IKNL januari t/m juni 2025

Wetenschappelijk overzicht IKNL januari t/m juni 2025

Auteur
A.M. Kuijpers-Ruurs

1 Niet-tumorspecifiek

1.1 Publicaties met impactfactor

Albers EA, de Ligt KM, van der Ploeg IM, Wouters MJ, Schagen SB, **van de Poll-Franse LV**. Screening for cognitive impairment in routine clinical oncology practice: a pilot study using patient-reported outcome measures and online cognitive testing in melanoma and breast cancer patients. *Support Care Cancer*. 2025 Mar 12;33(4):273. doi: 10.1007/s00520-025-09325-9. Impactfactor: 2,8

Bastings D, Schermer T, **van Roij J**, van den Beuken-Everdingen MH, Hendriks MP, van Laarhoven HW, Mandigers C, Smilde TJ, Sommeijer DW, Tromp C, Vriens B, **Raijmakers NJ**; eQuiPe Study Group. Emotional supportive care needs in patients with advanced cancer and their associated characteristics: a multicenter observational cohort Study (eQuiPe Study). *J Palliat Med*. 2025 Feb 19. doi: 10.1089/jpm.2024.0142. Online ahead of print. Impactfactor: 2,2

Boekel NB, **Verloop J**, van Boven HH, van Erp EJ, Schrijver L, Rookus MA, van Leeuwen FE. *Cancer risk after in utero exposure to diethylstilbestrol*. *Eur J Epidemiol*. 2025 May 28. doi: 10.1007/s10654-025-01234-9. Online ahead of print. Impactfactor: 7,7

Botta L, Didonè F, Lopez-Cortes A, Nieto AC, Desandes E, Hjalgrim LL, Jakab Z, Stiller CA, Zeller B, Gatta G, Pritchard-Jones K; BENCHISTA Project Working Group (**Visser O**, **Karim-Kos H**). International benchmarking of stage at diagnosis for six childhood solid tumours (the BENCHISTA project): a population-based, retrospective cohort study. *Lancet Child Adolesc Health*. 2025 Feb;9(2):89-99. doi: 10.1016/S2352-4642(24)00302-X. Impactfactor: 19,9

Breed FF, Breed WP, Dercksen MW, **Ezendam NP**, **Bijlsma MJ**, **van den Hurk CJ**. Shorter post-infusion cooling times at least as effective as longer cooling times: an observational study of taxane- and anthracycline-based chemotherapies in the Dutch Scalp Cooling Registry. *Support Care Cancer*. 2025 May 28;33(6):503. doi: 10.1007/s00520-025-09526-2. Impactfactor: 2,8

de Ligt KM, Hommes S, Vromans RD, Boomstra E, **van de Poll-Franse LV**, Krahmer EJ. Improving the implementation of patient-reported outcome measure in clinical practice: tackling current challenges with innovative digital communication technologies. *J Med Internet Res*. 2025 Feb 5;27:e60777. doi: 10.2196/60777. Impactfactor: 5,8

de Vries S, Francke K, Vervoort S, Pijnappel L, Milota M, **van der Linden Y**, Teunissen S, de Graaf E. Prioritizing the values, wishes, and needs of patients with advanced cancer: a secondary linguistic analysis. *Health Commun*. 2025 Feb 11:1-9. doi: 10.1080/10410236.2025.2462065. Online ahead of print. Impactfactor: 3,0

Dinnessen R, **Beijer S**, **Oerlemans S**, Husson O, **Mols F**, Bours MJ, **Ezendam NP**. Sleep quality and overall survival among cancer survivors in the Netherlands: a PROFILES registry study. *Sleep Med*. 2025 Apr 2;131:106488. doi: 10.1016/j.sleep.2025.106488. Online ahead of print. Impactfactor: 3,8

Forjaz G, Kohler B, Coleman MP, Steliarova-Foucher E, Negoita S, Guidry Auvil JM, Michels FS, Goderre J, Wiggins C, Durbin EB, **Geleijnse G**, Henrion MC, Altmayer C, Dubois T, Penberthy L. Making the case for an international childhood cancer data partnership. *J Natl Cancer Inst*. 2025 Jan 12:djaf003. doi: 10.1093/jnci/djaf003. Online ahead of print. Impactfactor: 10,0

Hemming L, **Duijts SF**, Cockburn C, Wilson C, Yuen EY, Spelten E. What do patients with a rare cancer living in rural, regional or remote areas and stakeholders want from a peer support program? a qualitative study. *BMC Cancer*. 2025 Feb 25;25(1):352. doi: 10.1186/s12885-025-13782-0.

Impactfactor: 3,4

Hoffstädt HE, Klapwijk MS, **Hartog ID, van der Linden YM**, Mertens BJ, **Stoppelenburg A**, van der Steen JT. Supporting family caregivers of nursing home residents with dementia in their last week of life: a survey among bereaved family caregivers. *Palliat Med Rep*. 2025 Mar 5;6(1):105-115. doi: 10.1089/pmr.2024.0088. eCollection 2025. Impactfactor: 1.1

Holtmaat K, van Beek FE, Wijnhoven LM, Custers JA, Aukema EJ, Eerenstein SE, van Oort IM, Werner JE, Wegdam JA, Jansen-Engelen IL, de Hingh IH, Verheul S, van der Beek DT, Wekking G, Steggerda I, Coupé VM, **Horevoorts N, de Korte AM, Lammens C**, Lissenberg-Witte BI, **de Rooij BH**, Prins JB, Verdonck-de Leeuw IM, Jansen F. Efficacy and budget impact of a tailored psychological intervention program targeting cancer patients with adjustment disorder: a randomised controlled trial. *Psychooncology*. 2025 Mar;34(3):e70123. doi: 10.1002/pon.70123. Impactfactor: 3,3

Janssen SH, van der Graaf WT, Hurley-Wallace A, **Vlooswijk C**, Padilla CS, Cairns C, Tyler CJ, Holthuis EI, Rohde GE, Hunt KJ, Way K, Angoumis K, Lankhorst LH, Engel MF, Rothmund MS, Reuvers MJ, Collaço N, Wagland R, Sodergren SC, Hanebaum S, Legendal T, Cartledge TJ, Bootsma TI, Bai Y, Darlington AS, Husson O. Core patient-centered outcomes for adolescents and young adults with cancer: a comprehensive review of the literature from the STRONG-AYA project. *Cancers (Basel)*. 2025 Jan 28;17(3):454. doi: 10.3390/cancers17030454. Impactfactor: 4,5

Janssen SH, **Vlooswijk C**, Bijlsma RM, Kaal SE, Kerst JM, Tromp JM, Bos ME, van der Hulle T, Lalisang RI, Nuver J, Kouwenhoven MC, van der Graaf WT, Husson O. Health-related quality of life of long-term adolescent and young adult (AYA) cancer survivors compared to a matched normative population: results of the SURVAYA study. *J Cancer Surviv*. 2025 Jun 17. doi: 10.1007/s11764-025-01818-0. Online ahead of print. Impactfactor: 3,1

Kapitan D, Heddema F, Dekker A, **Sieswerda M**, Verhoeff BJ, Berg M. Data interoperability in context: the importance of open-source implementations when choosing open standards. *J Med Internet Res*. 2025 Apr 15;27:e66616. doi: 10.2196/66616. Impactfactor: 5,8

Oerlemans S, Lodder P, van der Baan F, Giesinger JM, **Ezendam NP**. Development and validation of crosswalks between the EORTC QLQ-C30 physical, role, social and emotional functioning, fatigue and global health status/ quality of life scales and their corresponding PROMIS scales. *J Clin Epidemiol*. 2025 May 28;111853. doi: 10.1016/j.jclinepi.2025.111853. Online ahead of print. Impactfactor: 7,3

Smitsen DV, Lugtenberg M, Enting M, Beerepoot L, **Mols F**, Brouwers E, Wasowicz D, Joosen M. Getting back on track after treatment of cancer: a qualitative interview study of cancer survivors' experiences. *PLoS One*. 2025 Jan 9;20(1):e0313984. doi: 10.1371/journal.pone.0313984. eCollection 2025. Impactfactor: 2,9

van der Ven RG, Westra D, **van Erning FN, de Hingh IH**, Paulus A; OncoZON consortium. Going in circles?: Identifying the dissemination process of healthcare networks within their member organizations. *Soc Sci Med*. 2025 Jun 10;381:118311. doi: 10.1016/j.socscimed.2025.118311. Online ahead of print. Impactfactor: 4,9

van Velzen N, Brom L, van der Vorst MJ, Kiers ML, Wagemans MF, Kazimier H, **Boddaert MS, Raijmakers NJ**, Stoppelenburg A. Development of specialist palliative care in Dutch hospitals between 2014 and 2020: a repeated survey. *BMC Palliat Care*. 2025 Jan 23;24(1):20. doi: 10.1186/s12904-025-01657-x. Impactfactor: 2,5

Versluis MA, de Boer EC, **van de Poll-Franse LV, Raijmakers NJ, Vissers PA**, Dingemans IH, de Ruiter MB, Slingerland M, Reyners AK, Tesselaar ME, Wymenga AN. Differences in travel burden between

patients with self-reported curable and incurable cancer: results from a Dutch flash mob study. *Support Care Cancer*. 2025 Jun 23;33(7):610. doi: 10.1007/s00520-025-09675-4. Impactfactor: 2,8

Versluis MA, van der Linden YM, Oerlemans S, Sommeijer DW, de Jong WK, Baars A, Smilde TJ, van der Padt-Pruijsten A, **van de Poll-Franse LV, Raijmakers NJ**. Socioeconomic disparities in health-related quality of life and healthcare use in the last year of life of patients with advanced cancer: longitudinal results from the eQuiPe study. *Support Care Cancer*. 2025 Mar 11;33(4):265. doi: 10.1007/s00520-025-09309-9. Impactfactor: 2,8

Zegers AD, Motazed E, **de Heus E, Ho V**, Coenen P, Tamminga SJ, **Duijts SF**. Comparing loss of contractual employment pre- and post-diagnosis in patients with rare versus common cancer types: a national registry-based study. *J Cancer Surviv*. 2025 Jan 6. doi: 10.1007/s11764-024-01726-9. Online ahead of print. Impactfactor: 3,1

1.2 Overige publicaties

de Haan-Du J, Groenier KH, Kleefstra N, van der Vegt B, **Siesling S**, Landman GW, de Bock GH. Socioeconomic disparity in stage at cancer diagnosis among patients with type 2 diabetes in Dutch primary care: a cross-sectional study. *BMJ Public Health*. 2024 Mar 14;2(1):e000050. doi: 10.1136/bmjph-2023-000050. eCollection 2024 Jun.

Pasman R, Jacobs FJ, Eshuis R, de Kroon CD, **Sloep M, van der Werf J, Ebben KC**. Integrating real-world data and computational guidelines: designing a dashboard for nationwide evaluation of molecular diagnostics in oncology. *Stud Health Technol Inform*. 2025 May 15;327:1393-1397. doi: 10.3233/SHTI250631.

van Son D, Versluis MA, van de Poll-Franse LV, Raijmakers NJ. van Son D, Versluis MA, van de Poll-Franse LV, Raijmakers NJ. Kwaliteit van zorg en leven bij uitgezaaide kanker en hun naasten: inzichten uit de eQuiPe-studie. *NtvG* 169(2025)2(feb); 37-41.

van Vegchel T, Ebben KC. Using data-driven decision algorithms and real-world data for updating clinical practice guidelines. *Stud Health Technol Inform*. 2025 May 15;327:229-230. doi: 10.3233/ SHTI250312.

2 Borstkanker

2.1 Publicaties met impactfactor

Beenhakker L, Wijlens KA, Bode C, Vollenbroek-Hutten MM, [Siesling S](#), van Til JA, Witteveen A. Working toward personalized intervention advice: a survey study on preference heterogeneity in patients with breast cancer-related fatigue. MDM Policy Pract. 2025 Jan 13;10(1): 23814683241309676. doi: 10.1177/23814683241309676. eCollection 2025 Jan-Jun. Impactfactor: 1,9

Claassens EL, Ploumen RA, Kooreman LF, van Kats MA, [Siesling S](#), van Nijnatten TJ, Smidt ML. The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: a nationwide analysis. Breast. 2025 Feb 18;80:104425. doi: 10.1016/j.breast.2025.104425. Online ahead of print. Impactfactor: 5,7

[Dekker-Klaassen A](#), Drossaert CH, Folkert LS, Van der Lee ML, Guerrero-Paez C, Claassen S, Korevaar JC, [Siesling S](#); NABOR project group. Different needs ask for different care: breast cancer patients' preferences regarding assessment of care needs and information provision in personalized aftercare. Eur J Oncol Nurs. 2025 Mar 18;76:102873. doi: 10.1016/j.ejon.2025.102873. Online ahead of print. Impactfactor: 2,7

Ding N, Hermans KE, van Nijnatten TJ, Engelen SM, Tol J, Kooreman L, Vrancken-Peeters MT, [Siesling S](#), Voogd AC, Tjan-Heijnen VC, Geurts SM. Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: a population-based cohort study of systemically treated patients. Eur J Cancer. 2025 Apr 26;222:115475. doi: 10.1016/j.ejca.2025.115475. Online ahead of print. Impactfactor: 7,6

[Eijkkelboom AH](#), van Beek EJ, Stam MR, Westhoff P, [van Maaren MC](#), Sattler MG, Bantema-Joppe EJ, [Verheij M](#), van den Bongard DH, [Siesling S](#); NABON-COVID-19 Consortium and the COVID and Cancer-NL Consortium ([Verloop J](#)). Implementation of ultra-hypofractionated radiotherapy for breast cancer in the Netherlands in 2020-2023, using registry data and questionnaires. Radiat Oncol. 2025 Jun 12;20(1):99. doi: 10.1186/s13014-025-02669-w. Impactfactor: 3,3

[Godding LT](#), [Dekker-Klaassen A](#), Volders JH, van Hezewijk M, Siemerink EJ, van Uden D, Veltman J, [Eijkkelboom AH](#), [Siesling S](#). The added value of physical examination for breast cancer recurrence detection in women: a systematic review. Clin Breast Cancer. 2025 Jan 11:S1526-8209(24)00365-3. doi: 10.1016/j.clbc.2024.12.014. Online ahead of print. Impactfactor: 2,9

Hoveling LA, [Schoorman M](#), [Siesling S](#), van Asselt KM, Bode C. Diagnostic delay in women with cancer: what do we know and which factors contribute? Breast. 2025 Feb 19;80:104427. doi: 10.1016/j.breast.2025.104427. Online ahead of print. Impactfactor: 5,7

Hoveling LA, Heuken LP, Harfst T, [Schoorman MS](#), van Asselt KM, [Siesling S](#), Bode C. Understanding delays in breast cancer diagnosis in Africa: key insights and contributing factors. Int J Cancer. 2025 Jun 20. doi: 10.1002/ijc.70008. Online ahead of print. Impactfactor: 5,7

Jansen BA, Bargon CA, Bouman MA, van der Molen DR, Postma EL, van der Leij F, Zonneville E, Ruhe Q, Bruekers SE, Maarse W, [Siesling S](#), Young-Afat DA, Doeksen A, Verkooijen HM; UMBRELLA study group. Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy-results of the multicenter UMBRELLA breast cancer cohort. Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-025-07613-w. Online ahead of print. Impactfactor: 3,0

Jansen BA, Kelder JC, Borchert T, van Uden DJ, van der Leij F, Schröder C, Doeksen A, **Siesling S, van Maaren MC**, Postma EL. Trends in surgical treatment for cT4 breast cancer after neoadjuvant systemic therapy: a nationwide study in the Netherlands. *Ann Surg Oncol*. 2025 Jun 18. doi: 10.1245/s10434-025-17585-2. Online ahead of print. Impactfactor: 3,4

Jilderda MF, Zhang Y, Rebattu V, Salunga R, Mesker W, Wong J, **de Munck L**, Fornander T, Nordenskjöld B, Stål O, Anderson AL, Bastiaannet E, Treuner K, Liefers G. Identification of early-stage breast cancer with minimal risk of recurrence by breast cancer index. *Clin Cancer Res*. 2025 Mar 27. doi: 10.1158/1078-0432.CCR-24-3836. Online ahead of print. Impactfactor: 10,4

Koevoets EW, Schagen SB, May AM, Geerlings MI, Witlox L, van der Wall E, Stuiver MM, Sonke GS, **Velthuis MJ**, Jobsen JJ, van der Palen J, de Ruiter MB, Monninkhof EM. Effect of physical exercise on white matter microstructure in chemotherapy-treated breast cancer patients: a randomized controlled trial (PAM study). *Brain Imaging Behav*. 2025 Jan 13. doi: 10.1007/s11682-024-00965-9. Online ahead of print. Impactfactor: 2,4

Lammers SW, Geurts SM, Hermans KE, Kooreman LF, **Swinkels AC**, Smorenburg CH, van der Sangen MJ, Kroep JR, Honkoop AH, van den Berkmoortel FW, de Roos WK, Linn SC, Imholz AL, Vriens IJ, Tjan-Heijnen VC; Dutch Breast Cancer Research Group (BOOG) for the DATA investigators. The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial. *ESMO Open*. 2025 Feb 7;10(2):104154. doi: 10.1016/j.esmoop.2025.104154. Online ahead of print. Impactfactor: 7,1

Meurs CJ, Kerkhoven C, **Siesling S**, Menke-Pluijmers MB, Westenend PJ. ASO Visual Abstract: Surgery for classic, pleomorphic and nonclassic lobular carcinoma in situ surgery rate, risk of upstaging and short-term follow-up. *Ann Surg Oncol*. 2025 Feb 4. doi: 10.1245/s10434-025-16906-9. Online ahead of print. Impactfactor: 3,4

Stroot IA, Bart J, Hollema H, Wagner MM, Yigit R, van Doorn HC, de Hullu JA, Gaarenstroom KN, van Beurden M, van Lonkhuijzen LR, Slangen BF, Zweemer RP, Gómez Garcia EB, Ausems MG, Komdeur FL, van Asperen CJ, Adank MA, Wevers MR, Hooning MJ; HEBON Investigators (**Siesling S, Verloop J**); Mourits MJ, de Bock GH. High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers. *J Natl Cancer Inst*. 2025 Apr 1;117(4):719-727. doi: 10.1093/jnci/djae300. Impactfactor: 10,0

Tamminga SJ, de Wind A, Greidanus MA, Coenen P, Friberg E, Oldenburg HS, **Duijts SF**, de Boer AG. Prognostic factors for return to work in breast cancer survivors. *Cochrane Database Syst Rev*. 2025 May 7;5:CD015124. doi: 10.1002/14651858.CD015124.pub2. Impactfactor: 8,8

van Maaren MC, Voorham QJ, **Wijnen EM, de Munck L**, Wesseling J, **Visser O, Siesling S**. Notification of locoregional breast cancer recurrence based on pathology reports: a nationwide validation study with the Netherlands Cancer Registry. *Cancer Epidemiol*. 2025 Mar 5;96:102780. doi: 10.1016/j.canep.2025.102780. Online ahead of print. Impactfactor: 2,4

Vrancken Peeters NJ, Kerklaan R, **Vlooswijk C**, Bijlsma RM, Kaal SE, Tromp JM, Bos ME, van der Hulle T, de Boer M, Nuver J, Kouwenhoven MC, van der Graaf WT, Husson O. Long-term health-related quality of life among adolescent and young adult breast cancer survivors. *Qual Life Res*. 2025 Feb 21. doi: 10.1007/s11136-025-03914-1. Online ahead of print. Impactfactor: 3,3

Westenend PJ, Meurs CJ, **Siesling S**, Menke-Pluijmers MB. ASO Author Reflections: sentinel lymph node biopsy for patients with a non-classic lobular carcinoma In situ breast biopsy. *Ann Surg Oncol*. 2025 Jan 17. doi: 10.1245/s10434-024-16863-9. Online ahead of print. Impactfactor:3,4

2.2 Overige publicaties

Dekker-Klaassen A, Godding LT, van Hezewijk M, Korevaar JC, Wiegersma J, Drossaert CH, **Siesling S**; on behalf of the NABOR project group. [Perspectives of health care professionals on the value of physical examination for early detection of breast cancer recurrences: more than just a detection method?](#) Measurement and evaluations in cancer care 2025 3;100016.

3 Darmkanker

3.1 Publicaties met impactfactor

Boute TC, van Eekelen R, [Elferink MA](#), Lissenberg-Witte B, de Wilt JH, [Vink GR](#), Greuter MJ, Coupé VM. Follow-up adherence after treatment with curative intent for stage II and III colorectal cancer patients. *Cancer Med.* 2025 Mar;14(5):e70667. doi: 10.1002/cam4.70667. Impactfactor: 2,9

Darai A, Koëter T, [van Erning FN](#), van Alphen RJ, Verheul HM, Verheij M, Zimmerman DD, [Vissers PA](#), de Wilt JH. The role of adjuvant chemotherapy in rectal cancer: a nationwide cohort study from the Netherlands. *Colorectal Dis.* 2025 Mar;27(3):e70054. doi: 10.1111/codi.70054. Impactfactor: 2,9

de Nes LC, Tanis PJ, [Verhoeven RH](#), de Wilt JH, [Vissers PA](#). Impact of hospital volume on survival in patients with locally advanced colon cancer: a Dutch population-based study. *Colorectal Dis.* 2025 Feb;27(2):e17288. doi: 10.1111/codi.17288. Impactfactor: 2,9

Franken IA, van der Baan FH, Roodhart JM, Koopman M, [Vink GR](#), May AM, van Grevenstein WM. Reply to: Putting IDEA's results into practice: practicality should rule complexity in stage III colon cancer. *JCO Oncol Pract.* 2025 Apr 17:OP2500130. doi: 10.1200/OP-25-00130. Online ahead of print. Impactfactor: 4,7

[Galanos LJ](#), Rijken A, [Elferink MA](#), Kok NF, [van Erning FN](#), [De Hingh IH](#). Influence of a nationwide colorectal cancer screening program on the incidence of synchronous colorectal peritoneal metastases. *Int J Cancer.* 2025 Feb 17. doi: 10.1002/ijc.35356. Online ahead of print. Impactfactor: 5,7

Hanevelt J, [van Erning FN](#), de Vos Tot Nederveen Cappel WH, Vleggaar FP, van Westreenen HL, Moons LM. Trends over time and inter-hospital variation in the primary treatment approach for T1 colon carcinomas in the Netherlands. *Endoscopy.* 2025 Apr 27. doi: 10.1055/a-2595-5381. Online ahead of print. Impactfactor: 11,5

Kastelein A, [Mols F](#), Kervezee L, Chavannes NH, Gelderblom H, Neefjes J, Hinnen C. The impact of chemotherapy and body mass index on cancer-related fatigue in colon cancer patients: a PROFILES-registry study. *Cancer Med.* 2025 Jan;14(1):e70536. doi: 10.1002/cam4.70536. Impactfactor: 2,9

Kim H, [Shen L](#), Jeon J, Han YD, Han DH, Jung M, Shin SJ, You SC, Kim NK, Min BS, Hur H, Ahn JB, Shin SJ, van Gestel AJ, [van Erning FN](#), [Geleijnse G](#), Kim HS. Number of lymph nodes examined as a prognosis factor in patients with stage II or III colon cancer. *Clin Colorectal Cancer.* 2025 Feb 28:S1533-0028(25)00025-8. doi: 10.1016/j.clcc.2025.02.004. Online ahead of print. Impactfactor: 3,3

Linssen JD, Schafrat PJ, de Back TR, [van Erning FN](#), van Leerdam ME, Dekker E, Vermeulen L, [de Hingh IH](#), Sommeijer DW. Predisposing conditions in patients with small intestinal adenocarcinomas in the Netherlands: a 20-year nationwide cohort study. *Int J Cancer.* 2025 Feb 5. doi: 10.1002/ijc.35354. Online ahead of print. Impactfactor: 5,7

van den Berg K, [van Erning FN](#), Burger JW, van Hellemond IE, Roodhart JM, Koopman M, Rutten HJ, Creemers GJ. Treatment adherence to adjuvant chemotherapy according to the New Standard 3-month CAPOX regimen in high-risk stage II and stage III colon cancer: a population-based evaluation in the Netherlands. *Clin Colorectal Cancer.* 2025 Mar 1:S1533-0028(25)00027-1. doi: 10.1016/j.clcc.2025.02.006. Online ahead of print. Impactfactor: 3,3

van Gansewinkel EH, [van den Heuvel TB](#), [van Erning FN](#), [de Hingh IH](#), Bouwense SA, Simkens GA. Combined peritoneal and liver metastases in colorectal cancer: a Dutch nationwide population-based

analysis of incidence, treatment and survival. Eur J Surg Oncol. 2025 Mar 25;51(7):109999. doi: 10.1016/j.ejso.2025.109999. Online ahead of print.
Impactfactor: 3,5

van Nassau SC, Zwart K, van der Baan FH, **Vink GR, Elferink MA**, Snaebjornsson P, May AM, Koopman M, Roodhart JM. Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer: analysis of the Prospective Dutch Colorectal Cancer cohort. Int J Cancer. 2025 Mar 13. doi: 10.1002/ijc.35410. Online ahead of print.
Impactfactor: 5,7

3.2 Overige publicaties

Elferink MA, Galanos LJ, Sijtsma FP, Bijlsma MJ, Buffard TE, **de Hingh HJ**, van Leerdam ME, **van Erning FN**. Incidentie van darmkanker stijgt bij jonge mensen in Nederland: reden tot zorg. NtvG 169(2025)5(mei); 19-23.

4 Gynaecologische tumoren

4.1 Publicaties met impactfactor

Ebben KC, de Kroon CD, Schmeink CE, **van der Hel OL**, **van Vegchel T**, **Thissen M**, de Hingh IH, **van der Werf J**. Leveraging real-world data for continuous evaluation of computational clinical practice guidelines. *BMJ Health Care Inform*. 2025 May 12;32(1):e101333. doi: 10.1136/bmjhci-2024-101333. Impactfactor: 4,1

Olthof EP, **Wenzel HH**, van der Velden J, Stalpers LJ, **van der Aa MA**, Mom CH. Adjuvant chemoradiotherapy or radiotherapy alone for early squamous cervical cancer with a single surgical-pathological high-risk factor. *Cancers (Basel)*. 2025 Jun 18;17(12):2041. doi: 10.3390/cancers17122041. Impactfactor: 4,5

Olthof EP, **Wenzel HH**, **van Maaren MC**, van der Velden J, Spijkerboer AM, Bekkers RL, Beltman JJ, Slangen BF, Nijman HW, Smolders RG, van Trommel NE, Zusterzeel PL, Zweemer RP, Stalpers LJ, **van der Aa MA**, Mom CH. Radical hysterectomy or chemoradiotherapy for clinically early-stage cervical cancer with suspicious lymph nodes on imaging: a retrospective cohort study. *J Gynecol Oncol*. 2025 Mar;36(2):e16. doi: 10.3802/jgo.2025.36.e16. Impactfactor: 3,4

Said SA, Int'Hout J, Koffijberg H, de Hullu JA, Hyde SE, **van der Aa MA**, van Altena AM. External validation of prediction models for early relapse in advanced epithelial ovarian cancer using Australian and Dutch population-based data. *Cancer Epidemiol*. 2025 May 1;97:102824. doi: 10.1016/j.canep.2025.102824. Online ahead of print. Impactfactor: 2,4

van Erp MA, van Odenhoven AE, Burger JW, Ayez N, **Ezendam NP**, Boll D, Smedts HP, Piek JM. Enhancing multidisciplinary collaboration in ovarian cancer surgery. *Int J Gynecol Cancer*. 2025 Jan;35(1):100014. doi: 10.1016/j.ijgc.2024.100014. Epub 2024 Dec 17. Impactfactor: 4,5

Ye Y, **Timmermans M**, **van der Aa MA**, le Cessie S, Jonges GN, Janse JA, Gerestein CG. Effect of uterine manipulator on oncologic outcome in early-stage, low-grade endometrial cancer. *Int J Gynecol Cancer*. 2025 Feb;35(2):100047. doi: 10.1016/j.ijgc.2024.100047. Epub 2024 Dec 18. Impactfactor: 4,5

5 Hemato-oncologie

5.1 Publicaties met impactfactor

de Groot FA, Stedema FG, Kret EJ, de Haan LM, Jansen PM, Böhringer S, Diepstra A, van der Poel MW, Hamid MA, te Boome LC, Terpstra V, **Brink M**, Veelken H, de Groen RA, Dekker TJ, Nijland M, Vermaat JS. [MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis](#). *Haematologica*. 2025 May 29. doi: 10.3324/haematol.2025.287485. Online ahead of print.

Impactfactor: 8,2

Hermans SJ, Versluis J, van Werkhoven ED, van Norden Y, Janssen JJ, Huls GA, Pabst T, Breems DA, Berkx E, **Dinmohamed AG**, **Huijgens PC**, Sträng E, Hernández Rivas JM, Sobas M, Ayala Diaz R, Martinez Lopez J, Metzeler KH, Haferlach T, Thiede C, Uyl-de Groot CA, Bullinger L, Löwenberg B, Ossenkoppele GJ, Pignatti F, Cornelissen JJ. [Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients](#). *Br J Haematol*. 2025 May 26. doi: 10.1111/bjh.20185. Online ahead of print.

Impactfactor: 5,1

Kaplan ZL, van Leeuwen N, van Klaveren D, Eijkenaar F, **Visser O**, Posthuma EF, Zweegman S, Huls G, van Rhenen A, Blijlevens NM, Cornelissen JJ, van de Loosdrecht AA, Puijt JH, Levin MD, Hoogendoorn M, Lemmens VE, Lingsma HF, **Dinmohamed AG**. [The association between hospital volume and overall survival in adult AML patients treated with intensive chemotherapy](#). *ESMO Open*. 2025 Jan 30;10(2):104152. doi: 10.1016/j.esmoop.2025.104152. Online ahead of print.

Impactfactor: 7,1

Linschoten M, Geels J, van Werkhoven E, Visser-Wisselaar H, Chamuleau ME, Teske AJ, Robbers L, **Oerlemans S**, Crommelin H, Breems-de Ridder M, Schut A, Asselbergs FW, van Rhenen A; HOVON 170 DLBCL – ANTICIPATE consortium. [Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane](#). *Cardiooncology*. 2025 Jan 28;11(1):8. doi: 10.1186/s40959-025-00303-y.

Impactfactor: 3,2

Nijland M, Issa DE, Bult JA, Deeren D, Velders GA, Nijziel MR, Sandberg Y, Vergote VK, Oosterveld M, Fijnheer R, Brouwer R, Boersma R, Wu K, Nieuwenhuizen L, Vermaat JS, van Kampen RJ, Terpstra WE, Snauwaert S, van der Poel MW, de Jongh E, Durian M, Strobbe L, Beeker A, Gadisseur AP, van Rijn R, Visser OJ, Doorduijn J, Snijders TJ, Silbermann MH, de Jong D, Chamuleau ME, Mous R, Jalving M, Visser-Wisselaar H, Jansen van den Bergh S, Zwezerijnen GJ, Bremer E, **Brink M**, Diepstra A, Chitu DA, Koene HR, Zijlstra JM. [Atezolizumab consolidation in patients with high risk diffuse large B-cell lymphoma in complete remission after R-CHOP](#). *Blood Adv*. 2025 Apr 18;bloodadvances.2024015226. doi: 10.1182/bloodadvances.2024015226. Online ahead of print.

Impactfactor: 7,4

Pothast CR, Hofsink Q, Haggenburg S, Dijkland RC, van de Meent M, van Dijk K, Bhoekhan MS, Haverkate NJ, van Meerloo J, Falkenburg JH, de Groen RA, Broers AE, van Doesum JA, van Binnendijk RS, den Hartog G, Lissenberg-Witte BI, Kater AP, Smits GP, Wouters D, van Leeuwen EM, Bontkes HJ, Kootstra NA, **Vogels-Nooijen S**, van Baarle D, de Vries RD, van Meerten T, Mutsaers PG, Goorhuis A, Nijhof IS, Hazenberg MD, Heemskerk MH, Rutten CE; COBRA KAI study team. [T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines](#). *Haematologica*. 2025 May 29. doi: 10.3324/haematol.2024.287136. Online ahead of print.

Impactfactor: 8,2

Trama A, Geerdes EE, Demuru E, de Angelis R, **Karim-Kos HE**, Troussard X, Bennett D, Marcos-Gragera R, Kuehni CE, Liu H, Bernasconi A, Vener C, Guevara M, Zwaan CM, Mayer-da-Silva A, Paapsi K, Ragusa R, Smith OP; EUROCARE-6 Working Group. [Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: results from EUROCARE-6, a population-based study](#). *Eur J Cancer*. 2025 Mar 1;222:115336. doi: 10.1016/j.ejca.2025.115336. Online ahead of print.

Impactfactor: 7,6

van Lieshout R, Tick LW, Beckers EA, Biesbroek W, Custers S, Dieleman JP, Dijkstra M, Groenesteijn W, Heldens A, Hengeveld MM, Koene HR, Kranenburg S, van der Lee D, van der Put L, Rademakers N, Regelink JC, Regis M, Somer M, van Tilborg CJ, Westerweel PE, de Witte M, de Zeeuw S, Schouten HC, **Beijer S**. Associations of various medical nutrition therapy strategies with body composition, and physical and clinical outcomes in acute myeloid leukemia patients undergoing intensive remission-induction treatment: a multicenter prospective correlational study. Clin Nutr ESPEN. 2025 Mar 5:S2405-4577(25)00090-7. doi: 10.1016/j.clnesp.2025.02.028. Online ahead of print. Impactfactor: 2,9

Vener C, Lillini R, de Angelis R, Bonfarnuzzo S, Poirel HA, Trama A, **Visser O**, Troussard X, Marcos-Gragera R, Maynadié M, Demuru E, di Benedetto C, Johannesen TB, Solans M, Paapsi K, Guevara M, Mousavi SM, Blum M, von Moos R, Bennett D, Ragusa R, Guilloteau A, McShane CM, Rossi S, Sant M; EUROCare-6 Working Group (appendix pp 34-35). Long-term survival for myeloid neoplasms and national health expenditure: a EUROCare-6 retrospective, population-based study. Eur J Cancer. 2025 Jan 16;220:115231. doi: 10.1016/j.ejca.2025.115231. Online ahead of print. Impactfactor: 7,6

Zijlstra M, Snijders RA, de Boer F, Chamuleau ME, **Fransen HP, Oerlemans S**, van der Padt-Pruijsten A, Posthuma EF, **Visser O**, Zweegman S, **Raijmakers NJ, Dinmohamed AG**. Factors and considerations in no-treatment decisions in patients with key hematological malignancies: a nationwide, population-based study in the Netherlands. Eur J Haematol. 2025 Jan 29. doi: 10.1111/ejh.14390. Online ahead of print. Impactfactor: 2,3

6 Hoofdhalskanker

6.1 Publicaties met impactfactor

van den Bovenkamp K, Halmos GB, Slagter-Menkema L, [van Dijk BA](#), Yu S, Langendijk JA, van der Laan BF, Schuurung E, van der Vegt B. [The association between clinical outcome and expression of DNMT1, 3A, and 3B in locally advanced laryngeal carcinomas treated by definitive radiotherapy](#). *Cancers (Basel)*. 2025 May 22;17(11):1741. doi: 10.3390/cancers17111741. Impactfactor: 4,5

[van der Ven RG](#), [van Erning FN](#), Westra DD, [de Hingh IH](#), Paulus AT, Engelen SM, de Vries B, Nieuwenhuijzen GA; OncoZON network. [Nationwide trends and the impact of an oncology hospital network on reducing the burden of thyroid cytology procedures](#). *Int J Cancer*. 2025 May 2. doi: 10.1002/ijc.35462. Online ahead of print. Impactfactor: 5,7

7 Huidkanker

7.1 Publicaties met impactfactor

Eggermont CJ, Hollatz A, Wakkee M, [Louwman M](#), [Dinmohamed AG](#), Posthuma EF, Nijsten T, [Hollestein L](#). Skin cancer risk in over 200.000 patients with haematologic malignancies in 30 years; a nationwide population-based study in the Netherlands. Br J Dermatol. 2025 Jan 24;lja027. doi: 10.1093/bjd/lja027. Online ahead of print. Impactfactor: 11,0

Steijlen OFM, Pozza L, Traets JJ, Rentroia-Pacheco B, Eggermont CJ, Bellomo D, Alex S, Patel VA, Mooyaart AL, [Hollestein LM](#), Wakkee M. Enhanced metastatic risk stratification for cutaneous squamous cell carcinoma by combining clinical guidelines with the Erasmus MC model: results from two nationwide nested case-control studies. J Am Acad Dermatol. 2025 May 16:S0190-9622(25)02129-2. doi: 10.1016/j.jaad.2025.05.1390. Online ahead of print. Impactfactor: 12,8

Zhou C, Mooyaart AL, Kerkour T, [Louwman MW](#), Wakkee M, Li Y, Voorham QJM, Bruggink A, Nijsten TE, [Hollestein LM](#). The Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma. Eur J Epidemiol. 2025 Jan 9. doi: 10.1007/s10654-024-01188-4. Online ahead of print. Impactfactor: 7,7

8 Longkanker

8.1 Publicaties met impactfactor

[Katsimpokis D](#), [Aarts MJ](#), [Geleijnse G](#), Kunst P, [Bijlsma MJ](#). Income inequality and access to advanced immunotherapy for lung cancer: the case of Durvalumab in the Netherlands. J Clin Epidemiol. 2025 Feb 4;111711. doi: 10.1016/j.jclinepi.2025.111711. Online ahead of print.
Impactfactor: 7,2

Miguel JW, van Veen NL, Jacobs W, [Damhuis RA](#), van Uden-Kraan CF, van de Garde EM; Santeon VB Lung Cancer Research Group. Applied first-line systemic treatments, treatment modifications and outcomes in non-oncogenic metastatic non-small cell lung cancer in the Netherlands in 2019-2020: a nationwide study. Cancer Epidemiol. 2025 Apr 4;96:102809. doi: 10.1016/j.canep.2025.102809. Online ahead of print.
Impactfactor: 2,4

8.2 Overige publicaties

Choudhury A, Volmer L, [Martin F](#), Fijten R, Wee L, Dekker A, Soest JV. Advancing privacy-preserving health care analytics and implementation of the personal health train: federated deep learning study. JMIR AI. 2025 Feb 6;4:e60847. doi: 10.2196/60847.

9 Neuro-oncologie

9.1 Publicaties met impactfactor

van Dijck JT, Ardon H, Balvers RK, Bos EM, Bosscher L, Brouwers HB, **Ho VK**, Hovinga K, Kwee L, ter Laan M, Nabuurs RJ, Robe PA, van Geest S, van der Veer O, Verburg N, Wagemakers M, de Witt Hamer PC, Rodriguez Gironde M, Nandoe Tewarie RD; Quality Registry Neuro Surgery glioblastoma working group from the Dutch Society of Neurosurgery. [Survival prediction in glioblastoma: 10-year follow-up from the Dutch Neurosurgery Quality Registry](#). J Neurooncol. 2025 May 23. doi: 10.1007/s11060-025-05080-3. Online ahead of print.
Impactfactor: 3,2

Viozzi I, Hannink G, Ardon H, Balvers RK, Bosscher L, van Geest S, **Ho VK**, Hovinga K, Kwee L, Tewarie RN, Robe PA, van der Veer O, Wagemakers M, ter Laan M, de Witt Hamer PC. [Between-hospital variation in biopsy indication for patients with newly diagnosed glioblastoma in the Dutch Quality Registry for Neurosurgery](#). J Neurooncol. 2025 Feb 6. doi: 10.1007/s11060-025-04959-5. Online ahead of print.
Impactfactor: 3,2

10 Upper GI & HPB

10.1 Publicaties met impactfactor

Geerts JF, **Visser PA**, Mostert B, Wijnhoven BP, Haberkorn BC, Anten MG, Rosman C, Creemers GJ, Westdorp H, van der Sangen MJ, **Verhoeven RH**, Nieuwenhuijzen GA. Hospital variation in treatment for synchronous metastatic esophageal and gastric cancer: a nationwide population-based study in the Netherlands. *Int J Cancer*. 2025 Jun 5. doi: 10.1002/ijc.35491. Online ahead of print. Impactfactor: 5,7

Gehrels AM, **Visser PA**, Sprangers MA, Fijnheer NM, Pijnappel EN, **van der Geest LG**, Cirkel GA, de Vos-Geelen J, Homs MY, Creemers GJ, Stommel MW, Daamen LA, Besselink MG, Wilmink JW, van Laarhoven HW. Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study. *EClinicalMedicine*. 2025 Jan 21;80:103068. doi: 10.1016/j.eclinm.2024.103068. eCollection 2025 Feb. Impactfactor: 9,6

Graus MU, van Diepen AE, Josemanders K, Besselink MG, Bouwense SA, Daamen LA, de Hingh IH, de Jong EJ, van Laarhoven HW, de Meijer VE, Quintus Molenaar I, Stommel MW, Valkenburg-van Iersel LB, Wilmink JW, **van der Geest LG**, de Vos-Geelen J; Dutch Pancreatic Cancer Group. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: nationwide population-based study. *Eur J Cancer*. 2025 Mar 23;220:115385. doi: 10.1016/j.ejca.2025.115385. Online ahead of print. Impactfactor: 7,6

Guchelaar NA, de Neijls MJ, Noordman BJ, Graaf HE, van Hellemond IE, van der Sluis PC, Hoop EO, Lagarde SM, **Verhoeven RH**, Koolen SL, Luyer MD, de Hingh IH, van Laarhoven HW, Mostert B, Wijnhoven BP, Mathijssen RH. The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study. *EClinicalMedicine*. 2025 Feb 13;81:103109. doi: 10.1016/j.eclinm.2025.103109. eCollection 2025 Mar. Impactfactor: 9,6

Kamp D, Noya S, Mook S, Ruurda JP, Hillegersberg RV, Wang J, Jeene P, Brosens LA, May AM, **Verhoeven RH**, Laarhoven HW, Haj Mohammad N. Incomplete neoadjuvant chemo(radio)therapy negatively impacts pathological response and overall survival in locally advanced esophageal cancer. *Eur J Cancer*. 2025 May 31;224:115538. doi: 10.1016/j.ejca.2025.115538. Online ahead of print. Impactfactor: 7,6

Reijneveld EA, Kooij CD, Dronkers JJ, Kingma BF, Stel JM, Sauer M, van Hillegersberg R, van Duijvendijk P, **Beijer S**, Ruurda JP, Veenhof C; 'PRIOR study group' (**Velthuis MJ**). The course of physical fitness and nutritional status in patients following prehabilitation before esophageal cancer surgery: results from the PRIOR study. *Eur J Surg Oncol*. 2025 Jan 3;51(3):109575. doi: 10.1016/j.ejso.2025.109575. Online ahead of print. Impactfactor: 3,5

Slotman E, Pape M, van Laarhoven HW, Pouw RE, **van der Linden YM, Verhoeven RH Siesling S, Fransen HP, Raijmakers NJ**. Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: a real-world evidence study. *Int J Cancer*. 2025 Jan 9. doi: 10.1002/ijc.35314. Online ahead of print. Impactfactor: 5,7

Timmermans QM, de Hingh IH, **Elferink MA**, Wijnhoven BP, Schoon EJ, de Wilt JH, **van der Geest LG, Visser PA**. Trends in resection rates and postoperative mortality for gastrointestinal cancers between 2005 and 2020 in the Netherlands. *Eur J Cancer*. 2025 Apr 25;222:115469. doi: 10.1016/j.ejca.2025.115469. Online ahead of print. Impactfactor: 7,6

Tromp VN, Darsara RA, Crul M, Billingy NE, Westerdijk K, Veldt AA, Pieters CS, Westgeest HM, Bleckman RF, Velde IV, Hamberg P, Walraven I, **van den Hurk CJ**, Hugtenburg JG. The usefulness of the

ASSUSTENT application and ASSIST brochure in cancer patients using sunitinib. *Cancer Control*. 2025 Jan-Dec;32:10732748251343286. doi: 10.1177/10732748251343286. Epub 2025 May 24. Impactfactor: 2,5

van Laarhoven H, [Verhoeven RH](#), van Berge Henegouwen M, Mohammad NH, van Hillegersberg R, Slingerland M, Muijs CT, Wijnhoven B, Mostert B, Beerepoot L, Nieuwenhuijzen G, Derks S, van Rossum PS. Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands. *EClinicalMedicine*. 2025 Jan 22;80:103067. doi: 10.1016/j.eclim.2024.103067. eCollection 2025 Feb. Impactfactor: 9,6

van Zweeden AA, [van der Geest LG](#), Pijnappel EN, de Vos-Geelen J, van Hooft JE, Stommel MW, de Wit GF, Verheul HM, van Laarhoven HW, van der Vliet HJ, Wilmink JW; Dutch Pancreatic Cancer Group. Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. *Pancreatology*. 2025 Mar 27:S1424-3903(25)00064-X. doi: 10.1016/j.pan.2025.03.011. Online ahead of print. Impactfactor: 2,8

Wang HH, Nolte IM, [Verhoeven RH](#), Oppedijk V, van Etten B, Kats-Ugurlu G, Plukker JT, Hospers GA. Impact of extending the original criteria in the Chemoradiotherapy for Oesophageal Cancer followed by Surgery Study (CROSS) regimen on treatment outcome in locally advanced esophageal cancer patients. *ESMO Open*. 2025 May 15;10(5):105098. doi: 10.1016/j.esmoop.2025.105098. Online ahead of print. Impactfactor: 7,1

10.2 Overige publicaties

[Cara I](#), [van 't Hof N](#), Siegerink S, Veen L, [Geleijnse G](#), van Laarhoven H, [Verhoeven RH](#). Automating performance status annotation in oncology using Llama-3. *Stud Health Technol Inform*. 2025 May 15;327:868-869. doi: 10.3233/SHTI250483.

11 Urogenitale kanker

11.1 Publicaties met impactfactor

Beeren I, Meijer H, van der Heijden AG, **Aben KK**, Witjes JA, Kiemeny LA, Vrieling A. Fluid intake and recurrence and progression risk of patients with non-muscle-invasive bladder cancer. BJU Int. 2025 Jan 25. doi: 10.1111/bju.16665. Online ahead of print. Impactfactor: 3,7

Nuijens ST, van Hoogstraten LM, Terpstra NB, Beeren I, Vrieling A, **Wijnen EM**, Meijer RP, Kiemeny LA, Witjes JA, **Aben KK**. The impact of treatment for muscle-invasive bladder cancer on health-related quality of life. BJU Int. 2025 Apr 16. doi: 10.1111/bju.16736. Online ahead of print. Impactfactor: 3,7

Paulino Pereira LJ, van den Bergh RC, Sedelaar MJ, **Heesterman BL, Aben KK**, Kiemeny L, van Oort I, **van Melick HH**. Risk-based prostate-specific antigen monitoring reduces follow-up burden after radical prostatectomy. Eur Urol Oncol. 2025 May 5:S2588-9311(25)00049-5. doi: 10.1016/j.euo.2025.02.013. Online ahead of print. Impactfactor: 8,3

Ugalde-Morales E, Wilf R, Pluta J, Ploner A, Fan M, Damra M, **Aben KK**, Anson-Cartwright L, Chen C, Cortessis VK, Daneshmand S, Ferlin A, Gamulin M, Gietema JA, Gonzalez-Niera A, Grotmol T, Hamilton RJ, Harland M, Haugen TB, Hauser R, Hildebrandt MAT, Karlsson R, Kiemeny LA, Kim J, Lessel D, Lothe RA, Loveday C, Chanock SJ, McGlynn KA, Meijer C, Nead KT, Nsengimana J, Popovic M, Rafnar T, Richiardi L, Rocca MS, Schwartz SM, Skotheim RI, Stefansson K, Stewart DR, Turnbull C, Vaughn DJ, Winge SB, Zheng T, Monteiro AN, Almstrup K, Kanetsky PA, Nathanson KL, Wiklund F; Testicular Cancer Consortium. Identification of genes associated with testicular germ cell tumor susceptibility through a transcriptome-wide association study. Am J Hum Genet. 2025 Mar 6;112(3):630-643. doi: 10.1016/j.ajhg.2025.01.022. Epub 2025 Feb 24. Impactfactor: 8,1

van der Starre CM, Aben KK, van Leeuwen PJ, Busstra MB, Scheltema MJ, Bruins MH, Roelink H, van der Poel HG, de Jong IJ, **Heesterman BL**, Somford DM. Evaluation of short term surgical outcomes of radical prostatectomy in the decade following the introduction of minimum volume standards in the Netherlands. Urol Oncol. 2025 Apr 21:S1078-1439(25)00119-X. doi: 10.1016/j.urolonc.2025.03.020. Online ahead of print. Impactfactor: 2,4

van der Starre CM, Bangma CH, **Bijlsma MJ**, van den Bergh AC, Kiemeny LA, Kievit W, Vos K, Somford DM, Wildeman SM, **Aben KK**, de Jong IJ, Pos FJ, **Heesterman BL**. External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study. BMC Cancer. 2025 Jan 27;25(1):149. doi: 10.1186/s12885-025-13511-7. Impactfactor: 3,4

van Doeveren T, Remmers S, Boevé ER, Cornel EB, van der Heijden AG, Hendricksen K, Cauberg EC, Jacobs R, Kroon BK, Leliveld AM, Meijer RP, van Melick H, Merks B, Oddens JR, Pradere B, Roelofs LA, Somford DM, de Vries P, Wijsman B, Windt WA, Yska M, Zwaan PJ, **Aben KK**, van Leeuwen PJ, Boormans JL. Intravesical instillation of chemotherapy before radical surgery for upper urinary tract urothelial carcinoma: the REBACARE Trial. Eur Urol. 2025 Jan 21:S0302-2838(24)02759-3. doi: 10.1016/j.eururo.2024.12.006. Online ahead of print. Impactfactor: 25,3

van Doeveren T, **Aben KK**, van Leeuwen PJ, Boormans JL. Reply to Alexandra Masson-Lecomte. Bladder cancer recurrence following management of upper tract urothelial carcinoma: balancing prevention and iatrogenicity. Eur Urol. In press. <https://doi.org/10.1016/j.eururo.2025.01.004>. Eur Urol. 2025 Mar 17:S0302-2838(25)00151-4. doi: 10.1016/j.eururo.2025.02.028. Online ahead of print. Impactfactor: 25,3

van Doeveren T, **Aben KK**, van Leeuwen PJ, Boormans JL. Reply to Malshy et al, Vanthoor et al, and Ye et al. Letters to the editor re: Thomas van Doeveren, Sebastiaan Remmers, Egbert R. Boevé, et al.

Intravesical instillation of chemotherapy before radical surgery for upper urinary tract urothelial carcinoma: the REBACARE trial. Eur Urol. 2025 Jun 17:S0302-2838(25)00347-1. doi: 10.1016/j.eururo.2025.06.004. Online ahead of print. Impactfactor: 25,3

Vrieling A, Olsson LT, Kleuters G, Maurits JS, **Aben KK**, Sedelaar JP, Furberg H, Kiemeny LA. Pre- and post-diagnosis body weight trajectories in patients with localized renal cell cancer. Cancer Causes Control. 2025 Jan 6. doi: 10.1007/s10552-024-01957-2. Online ahead of print. Impactfactor: 2,2

Yildirim H, Aben KK, Bijlsma MJ, Postema AW, Aarts MJ, van Oijen MG, Bex A, Bins AD, Zondervan PJ. A nationwide real-world evaluation of upfront cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma in the immunotherapy era. Eur Urol Oncol. 2025 Apr 11:S2588-9311(25)00044-6. doi: 10.1016/j.euo.2025.02.011. Online ahead of print. Impactfactor: 8,3

Yildirim H, Richters A, Bins AD, Postema AW, Aarts MJ, van Oijen MG, Zondervan PJ, **Aben KK**. Immunotherapy in metastatic renal cell carcinoma: insights from a Dutch nationwide cohort. Eur Urol Open Sci. 2025 Feb 10;72:42-45. doi: 10.1016/j.euros.2025.01.008. eCollection 2025 Feb. Impactfactor: 3,2

11.2 Overige publicaties

Richters A, Suelmann B, Franken M, Mehra N, Rikhof B, Westgeest H, **Aben KK**, Robbrecht D; ProBCI Study Group. Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045. Cancer Treat Res Commun. 2025 Apr 15;43:100931. doi: 10.1016/j.ctarc.2025.100931. Online ahead of print.

Integraal Kankercentrum
Nederland
info@iknl.nl
www.iknl.nl

